TrialThoracic cancer2021

Phase II open-label multicenter study to assess the antitumor activity of afatinib in lung cancer patients with activating epidermal growth factor receptor mutation from circulating tumor DNA: Liquid-Lung-A.

Cheol-Kyu Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.